Search

EHA-HKSH Hematology Tutorial on Lymphoid Malignancies

Dates: April 25-26, 2020 
Location: Hong Kong
Chairs: G Gaidano, J Gribben, MF Law

In 2020 EHA will co-organize the first Hematology Tutorial in Hong Kong, together with the Hong Kong Society of Haematology (HKSH).

Read more

HemAffairs

HemAffairs holds your monthly dose of policy, regulatory and pharma news with impact on hematology in Europe. We also keep you abreast of relevant publications and events to keep an eye on. Enjoy the read! 

 

Read more

Press release: Breaking news on lymph node cancer and plasma cell cancer reported at Hematology Congress in Stockholm, June 13-16, 2013

In order to support high-quality science, the European Hematology Association (EHA) collaborates with 16 Scientific Working Groups (SWGs) and concentrates on fostering activities directed towards basic and translational research.

Read more

Treatment, medicine and hematology research: What patients want and doctors need (to know)

Jan Geissler, a Patient Advocate remarked about the Congress: “Over and above scientific updates, much can be achieved in partnership between hematologists and patients.

Read more

5th European CAR T-cell Meeting

The European Hematology Association (EHA) and the EBMT are excited to announce the 5th edition of the jointly organized European CAR T-cell Meeting.

Read more

European Hematology Association publishes new journal with Wolters Kluwer

The European Hematology Association, the largest Europe-based association of hematologists, launched its new journal HemaSphere with publisher Wolters Kluwer at the 22nd Annual Congress of EHA in Madrid.

Read more

EHA-IRSTH-IPHOS-SHRC Hematology Tutorial

 

         

In 2020 EHA will co-organize the 2nd Hematology Tutorial in Iran.

Read more

FDA Reports of Secondary Malignancies Following Chimeric Antigen Receptor (CAR) T Cell Therapies and Relative Risk: an EBMT-EHA-GoCART Coalition Statement

We need to bring your attention to the recent warning disseminated by the Food and Drug Administration (FDA) regarding T-cell lymphomas in patients undergoing Chimeric Antigen Receptor T-cell (CAR-T) therapy (1).

Read more